Vyne Therapeutics Net Worth
Vyne Therapeutics Net Worth Breakdown | VYNE |
Vyne Therapeutics Net Worth Analysis
Vyne Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vyne Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vyne Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vyne Therapeutics' net worth analysis. One common approach is to calculate Vyne Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vyne Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vyne Therapeutics' net worth. This approach calculates the present value of Vyne Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vyne Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vyne Therapeutics' net worth. This involves comparing Vyne Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vyne Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Vyne Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vyne Therapeutics' net worth research are outlined below:
| Vyne Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 424 K. Net Loss for the year was (27.87 M) with profit before overhead, payroll, taxes, and interest of 477 K. | |
| Vyne Therapeutics currently holds about 42.81 M in cash with (25.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
| Vyne Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 3469 shares by Iain Stuart of Vyne Therapeutics at 0.65 subject to Rule 16b-3 |
Vyne Therapeutics Quarterly Good Will |
|
Vyne Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vyne Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vyne Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Vyne Therapeutics Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vyne target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Vyne Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Strong Buy |
Most Vyne analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Vyne stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Vyne Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVyne Therapeutics Target Price Projection
Vyne Therapeutics' current and average target prices are 2.55 and 16.50, respectively. The current price of Vyne Therapeutics is the price at which Vyne Therapeutics is currently trading. On the other hand, Vyne Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Vyne Therapeutics Market Quote on 31st of May 2024
Target Price
Analyst Consensus On Vyne Therapeutics Target Price
Know Vyne Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vyne Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vyne Therapeutics backward and forwards among themselves. Vyne Therapeutics' institutional investor refers to the entity that pools money to purchase Vyne Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Vanguard Group Inc | 2024-03-31 | 69.6 K | Susquehanna International Group, Llp | 2023-12-31 | 60.3 K | Blackrock Inc | 2023-12-31 | 47.3 K | Renaissance Technologies Corp | 2023-12-31 | 46.4 K | Northern Trust Corp | 2023-12-31 | 37 K | Virtu Financial Llc | 2024-03-31 | 16.2 K | State Street Corporation | 2023-12-31 | 11.7 K | Millennium Management Llc | 2024-03-31 | 11 K | Hrt Financial Llc | 2023-12-31 | 10 K | Eventide Asset Management, Llc | 2024-03-31 | 1.4 M | Cormorant Asset Management, Llc | 2024-03-31 | 1.4 M |
Follow Vyne Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.63 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vyne Therapeutics's market, we take the total number of its shares issued and multiply it by Vyne Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Vyne Therapeutics' profitablity
Vyne Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Vyne Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Vyne Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Vyne Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Vyne Therapeutics' profitability requires more research than a typical breakdown of Vyne Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.32) | (0.34) |
When accessing Vyne Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Vyne Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vyne Therapeutics' profitability and make more informed investment decisions.
The data published in Vyne Therapeutics' official financial statements usually reflect Vyne Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Vyne Therapeutics. For example, before you start analyzing numbers published by Vyne accountants, it's critical to develop an understanding of what Vyne Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Vyne Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vyne Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Vyne Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vyne Therapeutics. Please utilize our Beneish M Score to check the likelihood of Vyne Therapeutics' management manipulating its earnings.
Evaluate Vyne Therapeutics' management efficiency
Vyne Therapeutics has return on total asset (ROA) of (0.3029) % which means that it has lost $0.3029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5191) %, meaning that it created substantial loss on money invested by shareholders. Vyne Therapeutics' management efficiency ratios could be used to measure how well Vyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of May 31, 2024, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.34. At present, Vyne Therapeutics' Net Tangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Total Current Assets are forecasted to decline to about 78.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.64 | 13.53 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 8.64 | 13.53 | |
| Enterprise Value Over EBITDA | 0.22 | 0.23 | |
| Price Book Value Ratio | 0.27 | 0.28 | |
| Enterprise Value Multiple | 0.22 | 0.23 | |
| Price Fair Value | 0.27 | 0.28 | |
| Enterprise Value | -26.1 M | -24.8 M |
The analysis of Vyne Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Vyne Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Vyne Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 10.0433 | Revenue 423 K | Quarterly Revenue Growth (0.01) | Revenue Per Share 0.021 | Return On Equity (0.52) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vyne Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vyne Therapeutics Corporate Filings
8K | 9th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 1st of March 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Vyne Therapeutics Earnings Estimation Breakdown
The calculation of Vyne Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Vyne Therapeutics is estimated to be -0.19 with the future projection ranging from a low of -0.19 to a high of -0.19. Please be aware that this consensus of annual earnings estimates for Vyne Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.19 Lowest | Expected EPS | -0.19 Highest |
Vyne Therapeutics Earnings Projection Consensus
Suppose the current estimates of Vyne Therapeutics' value are higher than the current market price of the Vyne Therapeutics stock. In this case, investors may conclude that Vyne Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Vyne Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2024 | Current EPS (TTM) | |
| 0 | 68.53% | -0.15 | -0.19 | -1.13 |
Vyne Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Vyne Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Vyne Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Vyne Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Vyne Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Vyne Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Vyne Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Vyne Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Vyne Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.24 | -0.15 | 0.09 | 37 | ||
2024-03-28 | 2023-12-31 | -0.5 | -0.2 | 0.3 | 60 | ||
2023-11-13 | 2023-09-30 | -0.76 | -2.01 | -1.25 | 164 | ||
2023-08-14 | 2023-06-30 | -1.99 | -3.09 | -1.1 | 55 | ||
2023-05-11 | 2023-03-31 | -2.61 | -1.74 | 0.87 | 33 | ||
2023-03-09 | 2022-12-31 | -3.24 | -3.33 | -0.09 | 2 | ||
2022-11-10 | 2022-09-30 | -3.12 | -2.88 | 0.24 | 7 | ||
2022-08-12 | 2022-06-30 | -3.06 | -2.34 | 0.72 | 23 | ||
2022-05-12 | 2022-03-31 | -2.97 | -2.52 | 0.45 | 15 | ||
2022-03-17 | 2021-12-31 | -4.26 | -3.6 | 0.66 | 15 | ||
2021-11-10 | 2021-09-30 | -5.8 | -6.48 | -0.68 | 11 | ||
2021-08-12 | 2021-06-30 | -6.37 | -6.3 | 0.07 | 1 | ||
2021-05-06 | 2021-03-31 | -7.34 | -6.66 | 0.68 | 9 | ||
2021-03-04 | 2020-12-31 | -9.6 | -9.9 | -0.3 | 3 | ||
2020-11-05 | 2020-09-30 | -12.03 | -10.8 | 1.23 | 10 | ||
2020-08-06 | 2020-06-30 | -17.88 | -14.4 | 3.48 | 19 | ||
2020-05-11 | 2020-03-31 | -38.88 | -68.4 | -29.52 | 75 | ||
2020-03-03 | 2019-12-31 | -59.47 | -64.08 | -4.61 | 7 | ||
2019-10-31 | 2019-09-30 | -55.56 | -50.4 | 5.16 | 9 | ||
2019-08-01 | 2019-06-30 | -60.62 | -49.68 | 10.94 | 18 | ||
2019-05-02 | 2019-03-31 | -58.18 | -58.32 | -0.14 | 0 | ||
2019-02-27 | 2018-12-31 | -58.32 | -54.72 | 3.6 | 6 | ||
2018-11-07 | 2018-09-30 | -63.79 | -40.32 | 23.47 | 36 | ||
2018-08-01 | 2018-06-30 | -56.88 | -25.92 | 30.96 | 54 | ||
2018-05-09 | 2018-03-31 | -47.88 | -51.84 | -3.96 | 8 | ||
2018-01-26 | 2017-12-31 | -49.44 | -129.6 | -80.16 | 162 | ||
2017-10-30 | 2017-09-30 | 0 | -0.53 | -0.53 | 0 | ||
2017-05-04 | 2017-03-31 | 0 | -1.08 | -1.08 | 0 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vyne Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Vyne Therapeutics Corporate Management
Elected by the shareholders, the Vyne Therapeutics' board of directors comprises two types of representatives: Vyne Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vyne. The board's role is to monitor Vyne Therapeutics' management team and ensure that shareholders' interests are well served. Vyne Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vyne Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Russell DPhil | VP Devel | Profile | |
| Iain Stuart | Chief Officer | Profile | |
| MS MD | Consultant | Profile | |
| David Schuz | VP Property | Profile | |
| Faad MD | Consultant | Profile | |
| Tyler Zeronda | Principal CFO | Profile |
How to buy Vyne Stock?
The net worth of Vyne Therapeutics is the difference between its total assets and liabilities. Vyne Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Vyne Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Vyne Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Vyne Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Vyne Therapeutics stock.Already Invested in Vyne Therapeutics?
The danger of trading Vyne Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vyne Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vyne Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vyne Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Vyne Stock analysis
When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Vyne Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.13) | Revenue Per Share 0.021 | Quarterly Revenue Growth (0.01) | Return On Assets (0.30) | Return On Equity (0.52) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.